Background and Purpose-The associations of individual long-chain n-3 polyunsaturated fatty acids with incident ischemic stroke and its main subtypes are not well established. We aimed to investigate prospectively the relationship of circulating eicosapentaenoic acid, docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA) with risk of total ischemic, atherothrombotic, and cardioembolic stroke. Methods-We measured circulating phospholipid fatty acids at baseline in 3 separate US cohorts: CHS (Cardiovascular Health Study), NHS (Nurses' Health Study), and HPFS (Health Professionals Follow-Up Study). Ischemic strokes were prospectively adjudicated and classified into atherothrombotic (large-and small-vessel infarctions) or cardioembolic by imaging studies and medical records. Risk according to fatty acid levels was assessed using Cox proportional hazards (CHS) or conditional logistic regression (NHS, HPFS) according to study design. Cohort findings were pooled using fixed-effects meta-analysis. Results-A total of 953 incident ischemic strokes were identified (408 atherothrombotic, 256 cardioembolic, and 289 undetermined subtypes) during median follow-up of 11.2 years (CHS) and 8.3 years (pooled, NHS and HPFS). After multivariable adjustment, lower risk of total ischemic stroke was seen with higher DPA ( Findings in each individual cohort were consistent with pooled results. Conclusions-In 3 large US cohorts, higher circulating levels of DHA were inversely associated with incident atherothrombotic stroke and DPA with cardioembolic stroke. These novel findings suggest differential pathways of benefit for DHA, DPA, and eicosapentaenoic acid.
S
troke is a leading cause of serious long-term disability and death in the United States. 1 On the basis of the randomized trials, long-chain n-3 polyunsaturated fatty acids (n-3 PUFAs), which include eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and docosapentaenoic acid (DPA), reduce major cardiovascular risk factors including hypertension, hyperlipidemia, and endothelial dysfunction, [2] [3] [4] supporting a potential protective effect against cardiovascular disease (CVD). However, the impact of these fatty acids on ischemic stroke incidence is not well established. For instance, observational studies demonstrate inverse associations of self-reported dietary consumption of n-3 PUFAs with ischemic stroke, 5 yet meta-analysis of randomized controlled trials found no effect of n-3 PUFA supplementation on stroke. 6 The latter findings were mostly from relatively short-term supplementation trials in high-risk patients with preexisting CVD in whom stroke was not a primary end point; thus, these findings may not be generalizable to habitual intake of n-3 PUFAs in primary prevention populations. 6 Consequently, the effects of n-3 PUFAs on incidence of ischemic stroke remain controversial.
In addition, ischemic stroke is a heterogeneous disorder with diverse pathophysiological pathways including atherothrombosis and cardioembolism, but most studies have not separately considered etiologic subtypes of ischemic stroke. 7 Effects of n-3 PUFAs may also differ across these subtypes. For instance, DHA may play a greater role in lowering risk of atherothrombotic stroke by reducing endothelial dysfunction and atherosclerosis, 4 whereas EPA and DPA may have a greater impact on cardioembolic stroke risk because of effects on clotting and atrial fibrillation. 8, 9 Finally, nearly all long-term studies of n-3 PUFA and stroke risk have estimated dietary n-3 PUFA intake from selfreported questionnaires. This limits the precision of evaluating different individual fatty acids, which are not well separated with dietary questionnaire data. In addition, self-reported dietary estimates might also be limited by random and systematic errors and reliance on accuracy of food composition databases.
To address these key issues, we measured circulating phospholipid levels of n-3 PUFAs and studied their associations with incidence of ischemic stroke, including subtypes of atherothrombotic and cardioembolic stroke, in 3 separate prospective US cohort studies: CHS (Cardiovascular Health Study), NHS (Nurses' Health Study), and HPFS (Health Professionals Follow-Up Study).
Methods

Population and Design
The design, enrollment, and population of CHS, NHS, and HPFS have been described (Figure 1) . 10, 11 In brief, CHS is a multicenter, community-based prospective cohort of older US adults. In 1989 to 1990, 5201 adults aged 65 years and older were randomly enrolled from 4 communities. A total of 687 additional black participants were similarly recruited and enrolled in 1992 to 1993. Trained study personnel performed annual clinic evaluations, including physical examination, diagnostic testing, blood sampling, and questionnaires on health status, medical history, and lifestyle. Among 3941 participants with available fatty acid measurements performed in 1992 to 1993, we excluded 266 participants with prevalent stroke or transient ischemic attack, resulting in 3675 participants included in our analysis. Each center's institutional review committee approved the study, and all participants provided informed written consent.
NHS is a prospective US cohort consisting of 121 701 female registered nurses 30 to 55 years of age enrolled in 1976 in 11 US states; HPFS is a prospective US cohort consisting of 51 529 US male health professionals 40 to 75 years of age enrolled in 1986 in the Boston area. In both cohorts, participants were followed through standardized questionnaires every 2 years on lifestyle, medical characteristics, and incident health outcomes. This analysis is based on a nested case-control study of incident ischemic stroke comprising 357 NHS and 80 HPFS participants (cases) with fatty acid measurements. The Human Subjects Research Committees at Brigham and Women's Hospital and at the Harvard School of Public Health approved the protocols for the studies. The participants' completion and return of the enrollment questionnaire implied informed consent.
Fatty Acid Measurements
In CHS, fatty acids were measured in stored blood samples from 1992 to 1993, the baseline year for this analysis. Blood was drawn after a 12-hour fast, stored at −70°C, and shipped on dry ice for longterm storage at −80°C. Total lipids were extracted from plasma, and phospholipids were separated from neutral lipids by 1-dimensional thin-layer chromatography. Fatty acid methyl esters samples were prepared by direct transesterification and separated using gas chromatography. 8 Plasma phospholipid fatty acid analysis provided quantitative measurement of fatty acids as a percentage of total fatty acids. Laboratory coefficients of variation were <3% for major fatty acids and also for EPA, DPA, and DHA. Identification, precision, and accuracy were continuously evaluated by using model mixtures of known fatty acid methyl esters and established in-house control samples. No evidence of degradation was observed after 10 years under the blood storage conditions in CHS. 12 In NHS, fatty acids were measured in stored blood samples from 1989 to 1990 and in HPFS from 1993 to 1994-the baseline years for this analysis. In both cohorts, blood samples were centrifuged and stored in aliquots of plasma and red blood cells and buffy coat fractions. 13 Samples were placed in liquid nitrogen freezers at −130°C to −196°C until required analysis. Fatty acid concentrations in erythrocyte phospholipids were analyzed by gas-liquid chromatography. 14 Detailed methods have been described elsewhere. 15 Concentrations of individual circulating fatty acids were expressed as a percentage of total fatty acids. Overall intra-assay coefficients of variation for phospholipid fatty acids in the 2 cohorts were 8.7% for EPA, 8.3% for DPA, and 6.9% for DHA. Fatty acid contents in blood samples stored at low temperatures were shown to be stable and had minimal degradation over more than a decade of storage. 
Follow-Up and End Point
In CHS, subjects were followed in alternating study clinic examinations and telephone contacts every 6 months through 2000 and biannual telephone contacts afterward till 2011. Less than 1% of total person-time was missing and censored early. Incident ischemic stroke was the primary end point in our analysis. Suspected cases of incident stroke were evaluated and adjudicated by a centralized events committee using available data from interviews, next of kin, death certificates, and medical records, including clinical work-up.
In NHS and HPFS, participants completed biennial follow-up questionnaires to update predisposing factors and report new onset of events including stroke. The biennial follow-up response rate exceeded 90% (95% on average). Participants were followed from baseline (time of blood collection) until the time of development of ischemic stroke. Incident cases of ischemic stroke were matched 1:1 with controls on risk-set sampling based on time of follow-up, age, race, smoking status, and time of blood collection, involving a maximum follow-up of 16 years for NHS and 10 years for HPFS with a pooled median follow-up of 8.3 years from baseline till the development of incident ischemic stroke. Controls were risk-set sample matched so their median follow-up will be the same as stroke events or cases.
Ascertainment of Ischemic Stroke
In CHS, a centralized study panel of neurologists blinded to other participant data reviewed all potential cases of stroke, using hospital records, test results, death certificates, and brain imaging findings.
Stroke
October 2017
ischemic stroke. In NHS and HPFS, a definite diagnosis of ischemic stroke subtype was made when computed tomographic scan, magnetic resonance imaging, angiography, echocardiogram, or autopsy confirmed the lesion. Detailed information on classification of ischemic stroke subtypes in CHS 19 and NHS/HPFS 20 has been reported.
Ascertainment of Covariates
In CHS, information on medical history, lifestyle, and other risk factors was collected during annual clinical visits using standardized interviews, physical examinations, and laboratory testing, 10, 21 including smoking, alcohol use, hypertension, diabetes mellitus, family history of CVD, and body mass index. Atrial fibrillation was identified on the basis of 12-lead resting ECGs performed as a part of the baseline examination. 22 Physical activity was assessed by using the modified Minnesota Leisure Time Activities scale. 23 Usual dietary habits were assessed using a food frequency questionnaire validated against 6 detailed 24-hour diet recall interviews spaced ≈1 month apart. 24 In NHS and HPFS, data on covariates were obtained via validated questionnaires including demographics, medical history, lifestyle, family history, and major CVD risk factors including smoking, 25 hypertension, and diabetes mellitus. 26 Height and weight were self-reported but showed high age-adjusted correlation coefficients with technicianmeasured values. 27 Physical activity and calculated metabolic equivalents (h/wk) were assessed using validated questionnaires based on self-reported average time spent on leisure time activities. 28 Usual dietary habits were measured using a semiquantitative food frequency questionnaire that was validated in a subsample of participants. 29 
Statistical Analysis
In each cohort, long-chain n-3 PUFA levels, measured as percent of total fatty acids, were evaluated in quartiles as indicator categories. Linear test for trends was performed by assigning the median value of the quartile to each category and entering this variable into the model as a continuous variable. Multivariable models were adjusted for potential confounders based on biological relevance, clinical interest, or association with the exposure or outcome, including age, sex, race, smoking, physical activity, alcohol intake, hypertension, family history of CVD and diabetes mellitus, menopausal status, body mass index, aspirin use, and intakes of fruits, vegetables, and meats. In CHS, multivariable-adjusted Cox proportional hazards analyses assessed the prospective relationship of circulating n-3 PUFAs and incident ischemic stroke and its subtypes, with time at risk from time of blood draw to the first stroke, death, or lost to follow-up. The proportional hazards assumption was not violated based on Schoenfeld residuals. In NHS and HPFS, conditional logistic regression models evaluated the corresponding prospective associations of circulating n-3 PUFAs and incident ischemic stroke and its subtypes. Given risk-set sampling in these 2 cohorts, coefficients from these models are directly analogous to Cox proportional hazards and estimate hazard ratios. Estimates were pooled across the 3 cohorts using fixed-effect meta-analysis. Multiple imputations (10-fold) were used for missing data for continuous variables and missing indicator variables for missing categorical variables. Statistical significance was defined as 2-tailed α=0.05. Analyses were performed using SAS 9.3 (SAS, Cary, NC).
Results
At baseline, participants in CHS were older (75.1±4.8) than participants in NHS (61.0±6.1) or HPFS (67.6±7.8; Table 1 ). Most participants were white: 88% in CHS, 98% in NHS, and 94% in HPFS. The 3 cohorts included broad mixtures of lifestyle, smoking, and dietary habits. Diabetes mellitus and hypertension were more prevalent in CHS at baseline. As expected, cases and controls in NHS and HPFS were similar in matching factors including age, race/ethnicity, and smoking. Median follow-up was 11.2 years in CHS and 8.3 years in NHS and HPFS (pooled). During follow-up, 953 incident ischemic strokes were identified, including 408 atherothrombotic, 256 cardioembolic, and 289 ischemic strokes with insufficient information for subclassification.
Phospholipid n-3 PUFAs and Risk of Ischemic Stroke
After adjustment for age, sex, race, smoking, physical activity, alcohol intake, family history of CVD and diabetes mellitus, hypertension, menopausal status, body mass index, aspirin use, and intakes of fruits, vegetables, and meats, lower risk of incident ischemic stroke was seen with higher circulating levels of DHA (comparing the top to bottom quartile; pooled hazard ratio [ When we evaluated atherothrombotic stroke in similarly adjusted analyses, participants in the highest compared with the lowest quartile of DHA had 47% lower risk (pooled HR, 0.53; 95% CI, 0.34-0.83; P-trend=0.001). In contrast, neither DPA nor EPA was significantly associated with atherothrombotic stroke. When we evaluated cardioembolic stroke, participants in the highest compared with the lowest quartile of DPA had 42% lower risk (pooled HR, 0.58; 95% CI, 0.37-0.92; P-trend=0.01). Neither EPA nor DHA was significantly associated with cardioembolic stroke (Figure 2) . Results for each cohort are presented in Tables I through III in the online-only Data Supplement.
Discussion
In 3 large, independent prospective US cohorts, we observed an inverse relationship between circulating levels of DPA and DHA and incident ischemic stroke. Among ischemic stroke subtypes, DHA was inversely associated with atherothrombotic stroke and DPA with cardioembolic stroke. These associations remained significant after adjustment for demographic, lifestyle, and vascular risk factors. In comparison, EPA was not associated with total ischemic, atherothrombotic, or cardioembolic stroke. These findings support the hypothesis that individual serum fatty acids have differential associations with total ischemic, atherothrombotic, and cardioembolic stroke.
A growing body of evidence from basic science and experimental research in the past decade indicates that DHA may exert protection against atherosclerosis through multiple pathways. 2 Atherothrombotic stroke is a consequence of atherosclerotic changes of the vascular surface and subsequent platelet activation at the site of vascular lesion. DHA lowers plasma triglycerides by reducing fatty acid availability for triglyceride synthesis because of decreased de novo lipogenesis and may also reduce insulin resistance and glucose intolerance. 30 Evidence also suggests that DHA, but not EPA, can lower resting heart rate and systolic and diastolic blood pressure by affecting cardiac electrophysiological pathways, as well as dilator and constrictor responses in microcirculation. 4, 31 Other mechanisms that may suggest a cause-effect association between DHA and atherothrombotic stroke include reduction of oxidative stress, inflammation, and endothelial dysfunction. 2, 32 In a Japanese cohort, DHA but not EPA was inversely associated with carotid intima-media thickness, consistent with our findings for atherothrombotic stroke and suggesting antiatherogenic effects of DHA. DHA is also the precursor to neuroprotectin D1, an anti-inflammatory docosanoid derivative which downregulates apoptosis and promotes cell survival in models of ischemic stroke. 33 Accumulation of DHA in the brain has been associated with reduced neuroinflammation 34 and activation of antiapoptotic pathways. Collectively, this evidence suggests that DHA may confer a protective effect on ischemic stroke, in particular atherosclerosis and atherothrombosis of the arteries feeding the brain.
In contrast to atherothrombotic stroke, cardioembolic stroke is mainly caused by several underlying pathophysiological mechanisms associated with arrhythmia, cardiac wall or chamber abnormality, or valvular disease. 35 Atrial fibrillation is the most important source of cardioembolic stroke, followed by left ventricular thrombus associated with myocardial infarction or congestive heart failure. 36 In vitro and animal studies and some human studies have suggested that n-3 PUFAs, including DPA, can prevent arrhythmia and reduce the onset of atrial fibrillation by directly influencing atrial and ventricular myocyte electrophysiology, as well as modulations in autonomic tone, or anti-inflammatory, or antifibrotic effects. 2 In a prospective evaluation of plasma n-3 PUFA biomarkers within CHS, total n-3 PUFA and DHA levels were significantly associated with lower risk of incident atrial fibrillation, 37 although the semiparametric analyses of DPA suggested possible trends toward protective associations at higher levels of this fatty acid. However, findings from randomized controlled trials have been mixed, mostly focusing on the recurrence or postoperative atrial fibrillation after cardiac surgery, 2,38 with a comprehensive meta-analysis (2687 patients from 8 randomized controlled trials) showing that n-3 PUFA 
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therapy reduces the incidence of postoperative atrial fibrillation (pooled odds ratio, 0.84; 95% CI, 0.71-0.99; P=0.03) using a fixed model. 39 Cardiac emboli may also originate in peripheral circulation (paradoxical emboli), consisting of embolic debris such as platelet aggregates, thrombus, and platelet thrombi. Experimental studies demonstrate differential inhibitory effects of n-3 PUFAs on cyclooxygenase 1 and cyclooxygenase 2 metabolism. In platelets, DPA is metabolized into 11-and l4-hydroxy DPAs by the lipoxygenase pathway. When platelets were incubated with DPA, this inhibited the cyclooxygenase enzyme thereby reducing the thromboxane A2 production from arachidonic acid. 40 In these experiments, DPA was the most potent inhibitor of cyclooxygenase 1 activity, possibly 10× more potent than EPA in inhibiting platelet aggregation. 41, 42 Of note, DPA is mainly derived from endogenous elongation from EPA, and DPA can also undergo conversion to EPA; therefore, our findings may reflect this biomarker of metabolism, rather than a direct cause-effect relationship. In comparison, in a controlled trial of 59 diabetic subjects, randomized to 4 g/d of EPA, DHA, or olive oil (placebo) for 6 weeks, DHA, but not EPA, reduced ex vivo collagen-stimulated platelet aggregation, but neither DHA nor EPA significantly affected platelet aggregation in response to platelet-activating factor or fibrinolytic markers including plasminogen activator inhibitor-1 antigen or tissue-type plasminogen activator antigen. 43 Accordingly, well-designed randomized trials are required to assess the observed relationships of DPA with ischemic stroke.
Few studies have evaluated associations of individual n-3 PUFA biomarkers with ischemic stroke subtypes. In a South Korean retrospective case-control study of 248 stroke patients (104 with cerebral atherosclerotic stenosis and 144 without cerebral atherosclerotic stenosis) and 215 nonstroke controls, phospholipid DHA was associated with lower risk of ischemic stroke associated with cerebral atherosclerotic stenosis (odds ratio, 0.59; 95% CI, 0.35-0.99). 44 In a prospective nested case-control study (964 matched pairs) of postmenopausal US women, circulating DHA and DPA, but not EPA, were inversely associated with incidence of total ischemic stroke. 5 DHA was associated with atherothrombotic stroke, but no significant association was confirmed between DPA and cardioembolic stroke (n=209 events), with wide CIs that included the possibility of benefit. Likewise, in a Korean retrospective case-control study of 120 subjects, a low level of total longchain n-3 PUFAs and DHA in erythrocytes was a risk factor for ischemic stroke, particularly small artery occlusion subtype, but this study was underpowered to draw conclusions on cardioembolic stroke, including only 40 patients with ischemic stroke. 45 No randomized trial has been conducted to investigate the effect of n-3 PUFAs in primary prevention of stroke. Previous randomized trials of n-3 PUFA supplementation have focused on coronary heart disease or total CVD in secondary prevention or high-risk populations. 46 These trials also may be limited by insufficient duration of follow-up (often 1-3 years) to detect effects on development of chronic diseases such as stroke. No previous trial has focused on stroke in a primary prevention setting. Our findings suggest that specific n-3 PUFA may benefit certain subtypes of ischemic stroke, supporting the need for additional well-conducted, prospective observational studies, mechanistic intervention studies, and controlled trials in primary prevention populations and with longer follow-up time. When interpreting our findings, potential limitations should be considered. Fatty acids were measured at baseline, and random changes in exposure over time would cause misclassification and attenuate findings toward the null. Systematic changes in exposure might also be possible. Caution should be used when interpreting associations of phospholipid fatty acids because these may reflect multiple factors, such as metabolism and selective incorporation into lipoproteins, in addition to intake. Because they are measured as percentage of fatty acids, their levels are influenced by other fatty acids, and the specific N-3 fatty acids may be measured with different degrees of precision. Consistent with clinical experiences, a subset of ischemic strokes, mainly in CHS, could not be reliably classified as atherothrombotic or cardioembolic, reducing statistical power. This was largely because of lack of records or full work-up at the time of the ischemic stroke event. Variations in etiologic classification systems of ischemic stroke across cohorts may have resulted in the dilution of effect and bias toward null for the association of fatty acids with each subtype of ischemic stroke. However, this would not affect the significance of our observed associations. We cannot exclude residual confounding by unknown or unmeasured factors. However, considering that findings remained significant after adjustment for major risk factors and the specificity of findings between certain n-3 PUFA and specific ischemic stroke subtypes, as well as biological plausibility based on experimentally observed effects of n-3 PUFA, suggest that Figure 2 . Risk of incident ischemic stroke, atherothrombotic stroke, and cardioembolic stroke according to the circulating phospholipid n-3 polyunsaturated fatty acid biomarkers in CHS (Cardiovascular Health Study), NHS (Nurses' Health Study), and HPFS (Health Professionals Follow-Up Study). Adjusted for age, sex, race, smoking, physical activity, alcohol intake, hypertension, family history of cardiovascular disease (CVD) and diabetes mellitus, menopausal status, body mass index, aspirin use, and intakes of fruits, vegetables, and meats. DHA indicates docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; HR, hazard ratio; and Q, quartile.
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confounding may not be the sole explanation for our findings. Our cohorts included mostly white Americans, which may limit generalizability to other ethnicities or races. Yet, we have little reason to think that biological effects of n-3 PUFA might vary according to race. Several strengths should be considered. Information on demographics, risk factors, and lifestyle was prospectively collected in a well-established multicenter cohort with little loss to follow-up, thus minimizing selection bias. We were able to evaluate each long-chain n-3 PUFA separately, while adjusting for multiple covariates, minimizing confounding. Consistency of our findings among the 3 cohorts increases their validity and generalizability.
In conclusion, we found that circulating DHA and DPA, but not EPA, are associated with lower risk of ischemic stroke, with differential associations with atherothrombotic versus cardioembolic stroke.
